Showing posts with label TXA127 granted FDA Fast Track Designation for treatment of DMD patients. Show all posts
Showing posts with label TXA127 granted FDA Fast Track Designation for treatment of DMD patients. Show all posts
Tuesday, November 17, 2015

Tarix Orphan's TXA127 granted FDA Fast Track Designation for treatment of DMD patients

›
Tarix Orphan LLC, a privately held biopharmaceutical company focused on the treatment of rare neuromuscular disorders and connective tissu...